Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and smaller biotechs saw a record-breaking $12.8bn raised by IPO and $20bn invested by venture financers.
Fortunes in the medical device industry were more divided. Companies developing diagnostics and treatments benefitted from the continued focus on COVID-19, but other segments suffered from decreased demand — a trend that could continue in 2021.